Quantitative multivoxel H-1 MR spectroscopy of the brain in children with acute liver failure by Sijens, Paul E. et al.
  
 University of Groningen
Quantitative multivoxel H-1 MR spectroscopy of the brain in children with acute liver failure
Sijens, Paul E.; Alkefaji, Heyder; Lunsing, Roelineke J.; van Spronsen, Francjan J.; Meiners,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2008
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Sijens, P. E., Alkefaji, H., Lunsing, R. J., van Spronsen, F. J., Meiners, L. C., Oudkerk, M., & Verkade, H. J.
(2008). Quantitative multivoxel H-1 MR spectroscopy of the brain in children with acute liver failure.
European Radiology, 18(11), 2601-2609. https://doi.org/10.1007/s00330-008-1049-z
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Eur Radiol (2008) 18: 2601–2609








Received: 16 January 2008
Revised: 22 February 2008
Accepted: 8 March 2008
Published online: 21 May 2008
# The Author(s) 2008
Quantitative multivoxel 1H MR spectroscopy
of the brain in children with acute liver failure
Abstract Acute liver failure
(ALF)-related encephalopathy was
previously characterized by MR
spectroscopy of single voxels con-
taining both grey and white matter
brain tissue. Quantitative multivoxel
MRS was used here to compare grey
and white matter brain tissue concen-
trations of glutamate/glutamine (Glx)
and lactate in ALF and associate the
results with other liver function
parameters. Five pediatric patients
with ALF-related encephalopathy and
five controls, examined after success-
ful liver transplantation, were exam-
ined by brain MRI/MRS. ALF
patients had higher Glx and lactate
concentrations in brain white matter
than controls (Glx + 125%: P<0.01;
lactate + 33%, P<0.05) and higher
Glx in grey matter (Glx + 125%: P<
0.01). Within the group of ALF
patients positive correlations were
found between grey or white matter
lactate concentration and serum am-
monia (P<0.05), and negative corre-
lations between grey or white matter
Glx and venous pH (P<0.001). This is
the first study presenting evidence of
high Glx levels in
both white and grey matter brain tissue
in ALF-related encephalopathy. The
elevations in CNS Glx and lactate
concentrations appear to relate to
hepatic detoxification (ammonia,
venous pH), rather than to liver pa-
renchymal integrity (aspartate amino-
transferase, alanine aminotransferase)
or biliary cholestasis (bilirubin,
γ-glutamyl transpeptidase, alkaline
phosphatase).
Keywords Acute liver failure .
Hepatic encephalopathy .
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Encephalopathy, a common and potentially life-threatening
complication of acute liver failure (ALF) [1, 2], is
predominantly a clinical diagnosis. Anatomical MRI
frequently does not show abnormalities [3]. Especially in
children, encephalopathy can be difficult to assess. There-
fore, the quest for additional diagnostic tools for assessing
the presence and severity of ALF-related encephalopathy
continues.
The recent availability of sensitive diagnostic tests, such
as magnetic resonance spectroscopy (MRS), allows us to
determine possible relationships between serum indicators
for liver function (total and indirect bilirubin, aspartate
aminotransferase, alanine aminotransferase) and param-
eters of CNS physiology in humans in vivo. The main cell
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metabolites in brain that can now be quantified by MRS are
choline, creatine, N-acetylaspartate, glutamate/glutamine
(Glx) and lactate. The detection limit of the MRS technique
is in the order of 0.1 mM. The power of MRS methodology
has improved substantially with the advent of multi-voxel
methods allowing for simultaneous assessment of grey and
white matter metabolism. Furthermore, technical improve-
ments allow for operator-independent automated postpro-
cessing and quantification of lactate signals. Previous
studies indicated increased Glx levels in brains of patients
with neonatal jaundice, with hepatic encephalopathy and
with ALF [4–7]. In previous documentations of brain MRS
results in ALF peak intensities were assessed qualitatively
by means of peak intensity ratios in one single voxel
containing both grey and white matter tissue [6, 7].
Although cutting edge at that time, the limitations of that
approach were that the results obtained in different patients
could not be compared in terms of specific metabolites and
could not differentiate between grey and white matter.
Moreover, the interpretations were based on the assump-
tion that results obtained in one small volume were
representative of the brain as a whole. In a recent MRS
study of cirrhotic patients with hepatic encephalopathy,
changes in MR spectra could be shown only for white
matter [8]. Much earlier, regional variations in the obtained
MRS metabolite ratios had already been pointed out,
suggesting that spectral information from more than one
voxel would be useful in the evaluation of patients with
hepatic encephalopathy [9].
In the present MRS study we therefore set out to quantify
both white and grey matter brain metabolism in pediatric
ALF patients with various degrees of encephalopathy, in
comparison with a control group of pediatric patients
without encephalopathy examined after liver transplan-
tation. A technical improvement compared with pre-
vious studies was the use of quantitative chemical shift
imaging allowing for direct comparison of curve-fitted
metabolite peak areas in arrays of multiple grey and
white matter voxels. We used methodology involving
operator-independent automated postprocessing and
quantification of Glx and lactate levels in CNS. Brain
metabolite concentrations were related to serum bilirubin
concentration and other blood parameters of liver function.
Patients and methods
Patients
Nine pediatric patients (age 3 months-11 year) were ex-
amined by brain MRI/MRS as part of a workup to assess the
state of the patient, either during screening for subsequent
treatment (patients 1–5) or as part of checkup after successful
transplantation (patient 4 second time, patients 6–9)
(Table 1). MRI of the latter patients was indicated to
investigate the presence of intracranial hypertension (pa-
tient 4 second time), intracranial lesions in syndrome of
Alagille (patients 6, 8), structural defects as the cause of
headaches (patient 7) or ischemic lesions after an epileptic
episode (patient 9). Patients 2–5 were diagnosed with
ALF, illustrated by a vitamin K-resistant coagulation
abnormality (an international normalized ratio INR ≥1.5)
[10] and any degree of mental alteration (encephalopathy)
at the time of MRS. Strictly speaking, patient 1 had “acute
on chronic” liver failure, with hepatic encephalopathy.
Encephalopathy was determined according to Suchy [11].
Patient 4 had ALF because of a non-functioning graft
after liver transplantation. The second MRS study in
patient 4 and those in patients 6–9 were performed
when they had neither ALF nor encephalopathy and
were used as controls, considering that their MR studies
were negative for all of the above-mentioned indica-
tions. This approach was based on institutional medical
ethical guidelines excluding the participation of young
healthy children as control group in MRI studies.
Table 2 gives the values of biochemical blood
parameters for biliary cholestasis (bilirubin, γ-glutamyl
transpeptidase, alkaline phosphatase), hepatic detoxifi-
cation (ammonia), protein synthesis (albumin) and liver
parenchymal integrity (aspartate aminotransferase, ala-
nine aminotransferase). Table 2 also provides venous
pH and lactate (bottom two rows) and the brain tissue
metabolite concentrations as determined by MRS in the
patients (top two rows). The indirect bilirubin concen-
trations were derived by subtracting direct bilirubin
from total bilirubin, both determined by routine
biochemical analysis. Reference values for bilirubin,
alkaline phoshatase and albumin were adopted from
Atallah et al. [12], those for γ-glutamyltranspeptidase,
aspartate aminotransferase and alanine aminotransferase
from Lee at al. [13]. Reference values for venous
ammonia samples, pH and blood lactate were based on
historical values from our own laboratory. The MRS
reference range for Glx and for lactate had been
obtained from our own MRS data base of age-matched
children without neurological problems. Our data cannot
be matched to previously published data from other
groups, because others have not differentiated between
grey and white matter and/or not summarized the
signals from different voxels necessary in order to be
able to quantify Glx and lactate signals. All MRI/MRS
examinations were performed with informed consent,
and blood samples were collected on the same day. The
missing values for blood lactate (patients 2, 3, 6, 7, 8)
and ammonia (patients 6, 7, 8) in Table 2 reflect lack of
clinically indication for having these determined on the
day of MRS. Patients 1–3 did not survive ALF or liver
transplantation, due to failing liver grafts and abstinence
from retransplantation because of progressive circulato-
ry insufficiency with multi-organ failure, ongoing ade-
novirus infection with circulatory insufficiency and/or
ongoing systemic yeast infection.
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Table 2 MR spectroscopy-derived brain tissue glutamate/glutamine and lactate concentrations and plasma concentrations of markers of
liver function in patients with acute liver failure and in liver transplant patients
Patient 1 2 3 4* 5 6 7 8 9 Reference values
Glx (mmol/l)
Grey matter 6.1 5.4 5.7 3.3/2.7 4.3 2.1 2.7 2.4 2.2 1.5–2.0**
White matter 5.4 3.9 4.4 2.4/1.9 3.1 1.2 2.3 1.7 1.2 1.0–1.5**
Lactate (mmol/l)
Grey matter 0.9 0.7 2.7 0.8/0.6 0.5 0.6 0.6 0.5 0.3 0–0.5**
White matter blood 0.6 0.4 1.9 0.4/0.3 0.3 0.3 0.3 0.3 0.2 0–0.5**
Ammonia (μmol/l) 154 65 234 50/30 45 n.d. n.d. n.d. 14 15–45
Bilirubin (μmol/l)
Total 1,272 180 196 257/10 163 6 10 6 66 0–17***
Direct 1,149 122 116 152/3 137 3 6 1 48
Indirect 123 58 80 105/7 26 3 4 5 18
γ-glutamyl transpept-idase (U/l) 87 35 26 73/185 52 18 100 13 1,099 5–63****
Alkaline phosphatase (U/l) 437 196 113 435/134 440 164 477 285 1,048 22–92***
Albumin (g/l) 33 26 24 35/38 35 40 40 42 29 38–54***
ASAT (U/l) 1437 2857 222 161/16 537 112 76 59 95 10–40****
ALAT (U/l) 437 3954 212 125/16 2,026 90 76 41 171 6–40****
Venous pH 6.99 7.42 7.27 7.55/7.51 7.47 7.38 7.38 7.36 7.43 7.28–7.43
Blood lactate (mmol/l) 13.4 n.d. n.d. 3.2/2.1 1.3 n.d. n.d. n.d. 2.5 0.5–2.0
ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; Glx, glutamate/glutamine; *values before/after transplant. Reference
values adopted from **our own experience in MRS examinations of near healthy children without neurological problems, ***Atallah et al.
[12] and ****Lee at al. [13]
Table 1 Clinical data of liver transplant patients examined by MRS




Cause of liver dysfunction
indicating liver transplantation
Encephalopathy score
at time of MRS
Other diagnostic
information
Acute liver failure at the time of MRI/MRS
1 F 5 months 1 week before Neonatal cholestasis ex causa
ingognita; acute on chronic liver failure
Grade I* Pyruvate kinase
deficiency
2 M 2 years 1 day before Acute liver failure due to
adenovirus infection
Grade IVa
3 M 5 years 1 week after Acute liver failure due to
hepatopulmonary syndrome
Grade IVb Systemic candida
infection; biliary atresia
4 M 5 years 1 day before Acute/subacute liver failure due
to cholangitis
Grade I
5 M 7 years Not realized Acute liver failure, possibly due
to edonovirus infection
Grade III
No acute liver failure at the time of MRI/MRS
6 F 3 years 1 year after Alagille’s syndrome None Periphery pulmonalis
stenosis
7 M 4 years 1.5 years after Biliary atresia due to cholangitis None
4 M 5 years 2 weeks after Acute liver failure due to cholangitis None
8 F 8 years 5 years after Alagille’s syndrome None Periphery pulmonalis
stenosis
9 M 11 years 2 weeks after Biliary atresia None
*A grade of I at the day of MRS and III/IV 2 days earlier
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MR spectroscopy
MRI and proton (1H) MRS were performed using an
eight-channel transmit/receive head coil of a 1.5-T
Magnetom Sonata system (Siemens AG, Erlangen,
Germany). The MRI protocol consisted of transverse
T2-weighted fast spin-echo, T2-weighted gradient
echo, fluid attenuated inversion recovery (FLAIR),
inversion recovery and diffusion-weighted imaging
(DWI) covering the entire brain. Sagittal T1-weighted
spin-echo and coronal T2-weighted fast spin-echo were
also acquired. Two-dimensionalchemical shift imaging
(CSI) point resolved spectroscopy measurement with a
repetition time (TR) of 1,500 ms and an echo time
(TE) of 135 ms [14]. A transverse T2-weighted fast
spin-echo series was used as guidance for examining
an approximately 7×7×2 cm3 supraventricular volume
of interest (i.e., located cranial to the ventricles). Use
of a 16×16 phase encoded field of view of 16×
16 cm2 resulted in MRS voxels of 1×1×2 cm3 (7 min
acquisition time). The number of peaks fitted included
the chemical shift ranges restricted to 3.1–3.3 ppm for
choline, 2.9–3.1 for creatine, 2.2–2.4 for glutamate/
glutamine (Glx), 1.9–2.1 for N-acetyl aspartate, and
1.2–1.4 for lactate. Using a standardized postprocessing
protocol, the raw data were processed automatically,
allowing for operator-independent quantifications. The
CSI voxels on the edge of the volume of interest (subject
to signal drop-off) were deducted from the total data
matrix. The inner 36 voxels were analyzed and separated
into the two central columns mainly containing grey
matter (12 voxels) and the remainder of 24 voxels filled
with white matter (Fig. 1, right side) [15]. Grey matter and
white matter patient metabolite levels were determined
relative to grey matter creatine as internal reference (set at
6.2 mM) [15].
Statistical analysis
In patients with ALF-related encephalopathy (n=5)
and in controls (n=5), correlations between parameters
for samples without normal distributions were eval-
uated by assessment of Spearman’s rank correlation
coefficient (two-tailed). Kruskal-Wallis test was used
for analyzing the asymptotic significance of differ-
ences between multiple pairs of independent samples.
The two sets of divergent results in the one patient
examined both before and after liver transplantation
(patient 4) were both included, based on the observa-
tion that the second data set reflected a condition
without ALF. This resulted in respective ALF and
control group sizes of five and two for ammonia, of
three and two for blood lactate and of five and five for
all other parameters.
Results
The concentrations of ammonia, bilirubin, alkaline phos-
phatase, aspartate aminotransferase and alanine amino-
transferase in blood and the MRS measured Glx and lactate
levels in the brain exceeded the reference values in the five
ALF patients (Table 2). Figure 1 shows normal MRS grey
matter spectra of a control patient (patient 9; Fig. 1a) and
high concentrations of Glx and lactate in an ALF patient
(patient 3; Fig. 1b). Patient 3 also had strongly elevated
ammonia and bilirubin levels (Table 2). In patient 5, the
blood ammonia and CNS lactate levels were normal. The
high CNS lactate concentrations in ALF patients 1 and 3
were paralleled by elevated lactate concentrations in blood
(patient 1) and reduced venous pH (patients 1 and 3).
Compared with the ALF group, the concentrations of
bilirubin, aspartate aminotransferase, alanine amino-
transferase, albumin and of Glx measured by MRS
were significantly lower in the control patients
(Table 3; 0.009 ≤ P≤0.046). Ammonia and CNS grey
matter lactate levels were also lower in control patients,
but this did not reach the level of statistical
significance (P=0.053 and 0.056, respectively; white
matter lactate: P=0.019). Figure 2 illustrates that the
concentrations of Glx in the grey and white matter
brain tissue and of bilirubin in blood exceeded those in
the non-ALF controls, without any overlap in the respective
concentration ranges (Table 2; P<0.01, each).
Within the ALF group, grey and white matter Glx
correlated inversely with venous pH (rsp=-1.00, P<0.001,
both), whereas grey and white matter lactate showed
significant rank correlation with ammonia (rsp=0.90, P=
0.037; and rsp=0.98, P=0.005, respectively; Fig. 3).
Figure 4 illustrates the relationship between encephalop-
athy grades and either Glx in the grey and white matter or
lactate (not significant). The levels of choline and N-acetyl
aspartate showed no significant variation among the ten
pediatric patients and subgroups, and were similar to those
in (near) healthy children of the same age (not shown). The
control Glx and lactate levels slightly exceeded/were
similar to the corresponding reference levels (Glx grey
matter 2.1–2.7 vs. 1.5–2.0; Glx white matter 1.2–2.3 vs.
1.0–1.5; lactate grey matter 0.3–0.6 vs. 0–0.5; lactate white
matter 0.2–0.3 vs. 0.5 mmol /l) (Tables 1, 2).
According to recent analyses glutamate has resonance
groups centered at resonance frequencies of 2.10 ppm
(β-CH2), 2.37 ppm (γ-CH2) and 3.78 ppm (α-CH) and
glutamine resonates at 2.14 ppm, 2.46 ppm and 3.80 ppm
[16–18]. In the spectra of Fig. 1, no peak is discernable
near 2.1 ppm (probably too close to the intense N-acetyl
aspartate peak), but well-defined peaks near 2.34 ppm
and at 3.78 ppm are found. The position of the γ-CH2
Glx at 2.34 ppm in all ALF patients and controls
indicates that the main component of the Glx peaks in




Our MRS study of ALF patients with encephalopathy
allows for the first time the comparison in terms of specific
metabolites in different patients, differentiation between
grey and white matter, and finally, results that could
reasonably be considered representative of the brain as a
whole. We compared brain metabolism in pediatric ALF
patients with various degrees of encephalopathy with a
control group. ALF patients had higher Glx and lactate
concentrations in brain white matter than controls (Glx +
125%: P<0.01; lactate + 33%, P<0.05) and higher Glx in
grey matter (Glx + 125%: P<0.01). Two patients from the
control group had their MRS examination just 2 weeks
after liver transplantation as compared with 1 to 5 years in
the others. This may have had a negative impact on the
differentiation of ALF patients from controls, as illustrated
by the comparatively high bilirubin, low albumin and high
blood lactate level in patient 9.
Within the group of ALF patients, positive correlations
were found between grey or white matter lactate concen-
tration and serum ammonia (P<0.05), and negative
correlations between grey or white matter Glx and venous
pH (P<0.001). The chemical shift position of the γ-CH2
resonance of Glx (near 2.34 ppm in all MR spectra)
suggested that the Glx elevation in grey and white matter
brain tissue of ALF patients was predominantly due to
glutamate rather than to glutamine.
Using multivoxel 1H MRS can give us information about
the distribution of metabolite concentrations throughout the
brain. The distribution between different areas of grey and
white matter would be of interest by providing information
a
b
Fig. 1 1H-MR spectra of grey matter brain tissue near the
interhemispheric fissure in two patients after liver transplantation,
patients 9 (a) and 3 (b) (TR/TE=1,500/135 ms), together with the
corresponding 6×6 spectral maps projected upon MR images
showing the transverse dimensions of the volume of interest. In
patient 3 (b), suffering from acute liver failure and hepatic
encaphalopathy, the Glx peaks at 2.36 and 3.78 ppm are elevated
and an inverted lactate doublet signal is seen at 1.33 ppm
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about selective vulnerability of the brain, possibly related to
the degree of activity, neuronal density or other factors. This
could possibly help to differentiate between different
patterns of injury and prognosis. In our study we used 2D
CSI, having the advantage of the acquiring of MRS
measurements in 7 min and the disadvantage that only one
plane of voxels is sampled without the option of retro-
spective positioning in the transverse direction. One would
have to resort to more time-consuming 3D CSI examina-
tions in order to assess metabolite concentrations through-
out the brain, which is not an option in pediatric MRI
studies. Another thought is to include the results of
diffusion-weighted imaging (diffusion tensor imaging) in
the evaluations of ALF patients and correlate the MRS
findings with the spatial distributions of the apparent
diffusion coefficients (and fractional anisotropy). That was
not done in this study because some of our earliest patients
were not examined by diffusion-weighted imaging.
Glutamate/glutamine (Glx)
Numerous studies have shown the accumulation in the
CNS of glutamine, considered to be an indicator of the
exposure of the brain to ammonia in ALF [19]. It has been
proposed that patients with hepatic encephalopathy have
increased cerebrospinal fluid glutamine concentrations

























Fig. 2 Plots of brain tissue glutamate/glutamine concentration
against blood plasma total bilirubin concentration. Closed symbols,
acute liver failure patients; open symbols, controls; circles, grey
matter brain tissue; triangles, white matter brain tissue
Table 3 Median plasma concentrations of markers of liver function
and MR spectroscopy derived brain tissue glutamate/glutamine and
lactate concentrations in the five acute liver failure patients (patients
1–3, 4 before transplant, 5) compared with the five patients without
acute liver failure at the time of MRS (patients 4 second time, 6–9)
Acute liver failure (n=5) No acute liver failure (n=5) P
Glutamate/glutam. (mmol/l)
Grey matter 5.4 (3.3–6.1) 2.4 (2.1–2.7) 0.009
White matter 3.9 (2.4–5.4) 1.7 (1.2–2.3) 0.009
Lactate (mmol/l)
Grey matter 0.8 (0.5–2.7) 0.6 (0.3–0.6) 0.056
White matter 0.4 (0.3–1.9) 0.3 (0.2–0.3) 0.019
Ammonia (μmol/l) 65 (45–234) 22 (14–30) 0.053
Bilirubin (μmol/l)
Total 196 (163–1272) 8 (6–66) 0.009
Direct 137 (116–1149) 3 (1–48) 0.009
Indirect 80 (26–123) 5 (3–18) 0.009
γ-glutamyl transpeptidase (U/l) 52 (26–87) 100 (13–1099) 0.602
Alkaline phosphatase (U/l) 435 (113–437) 285 (134–1048) 0.753
Albumin (g/l) 33 (24–35) 40 (29–42) 0.046
ASAT (U/l) 537 (161–2857) 76 (16–112) 0.009
ALAT (U/l) 437 (125–3954) 76 (16–171) 0.016
Venous pH 7.42 (6.99–7.55) 7.38 (7.36–7.51) 0.917
ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase, lactate omitted because of a lack of data
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enzyme glutamine synthetase located in the astrocytes [5].
High glutamine concentrations have been observed in
cerebrospinal fluid, serum, extracellular fluids and tissue
extracts of patients with ALF [18]. Although it is
conceivable that brain glutamine participates in the devel-
opment of hepatic encophalopathy, glutamine per se is not
neuronally active, and therefore its increase is unlikely to
cause the neuroinhibitory characteristic of encephalopathy
[20]. A demonstration of elevated concentrations of the
neurotoxic [21] amino acid glutamate rather than glutamine
in brain would therefore be of clinical relevance. Our study
indeed provides strong indications of high glutamate levels
in human grey and white matter tissue in ALF-related
encephalopathy. In the previous study involving ALF
patients (four children), McConnal et al. did not evaluate
the (in their case comparatively small) peak near 2.3 ppm.
Rather these scientists interpreted the presence of an
intense peak at 3.75 ppm as evidence that the Glx peak
represented glutamine [7]. In our data, however, the
position of the γ-CH2 Glx at 2.34 ppm in all ALF patients
and controls indicates that the main component of the Glx
peaks in the white and grey matter brain tissue of ALF
patients and controls is glutamate. Considering that sharply




















































a bFig. 4 Plots of brain tissue
glutamate/glutamine (a) and
lactate concentration (b) against
encephalopathy grade (a).
Closed symbols, acute liver
failure patients; open symbols,
controls; circles, grey matter


















































a bFig. 3 Plots of brain tissueglutamate/glutamine concentra-
tion against venous pH (a) and
of brain tissue lactate concen-
tration against the ammonia
concentration in blood (b).
Closed symbols, acute liver
failure patients; open symbols,
controls; circles, grey matter
brain tissue; triangles, white
matter brain tissue
2607
been observed in ALF, up to a concentration of
0.268 mmol/l [22], the possibility of part of the Glx signal
representing extracellular rather than intracellular gluta-
mate should be considered. We conclude that of the total of
up to 6 mmol/l Glx observed in the brains of ALF patients
(Table 2), up to 5%might have been extracellular glutamate.
Given the absence of sensitive parameters for enceph-
alopathy, we determined the relationships between Glx and
lactate with the traditional liver function parameters. Our
observation of strong negative rank correlations between
grey and white matter Glx and venous pH in patients with
ALF-related encephalopathy (Fig. 3a) suggests a relation-
ship between blood parameters and brain metabolism. This
interpretation would accord with an observation by Silva et
al. that the uptake of glutamate by cultered rat astrocytes is
inhibited at pH values of 7.4 to 7.8 as compared with pH=
7.0 [23]. We conclude that our present data are best
explained by the concept that the increased brain tissue Glx
in ALF might represent increased glutamate concentra-
tions, partly associated with pH decrease. The pH of blood,
though generally associated with ALF-related lactic aci-
dosis [24], did not significantly correlate with brain lactate
concentration.
Lactate
In ALF patients the serum concentrations of ammonia
correlated significantly with grey and white matter lactate
concentration (Fig. 3b, closed symbols), indicating that
white matter lactate as well as grey and white matter Glx
could be considered as markers of cerebral consequences
of ALF. The lack of differences for the most specific
indicators of cholestasis (γ-glutamyl transpeptidase, alka-
line phosphatase) between the ALF and control groups
(Table 3) and the observed lack of correlation between the
MRS determined CNS metabolites with the concentrations
of γ-glutamyl transpeptidase and alkaline phosphatase in
blood indicates that (chronic) cholestasis per se does not
influence brain Glx and lactate levels.
The neurological impact of cholestasis
Hepatic encephalopathy has been associated with increased
blood ammonia concentrations and with neurotoxicity
mediated by cerebral ammonia conversion into amino acids
such as glutamate and glutamine [16]. Indeed, the five
patients with hepatic encephalopathy had relatively high
blood ammonia concentrations, although in general ALF
patients had higher CNS Glx and lactate concentrations
than the controls (Table 3). There were no significant
differences in CNS Glx and lactate levels between low and
high grade encephalopathy patients (compare grade 1 with
grades 3/4) (Fig. 4). This lack of difference may reflect the
small number of patients and/or difficulty in scoring the
encephalopathy grade reliably, because of sedation and/or
young age.
In children with ALF CNS concentrations of Glx (grey
matter, white matter) and lactate (white matter) are
increased as compared with controls. Our study contrasts
with a previous study of cirrhotic patients reporting hepatic
encephalopathy changes in MR spectra in white matter
only [8]. In the latter study the spectra in grey matter
regions such as basal ganglia and frontal cortex were prone
to artifacts; however, this was not the case in the present
study. Here we have shown for the first time that grey and
white matter Glx levels in ALF correlate inversely with
venous pH, whereas grey and white matter lactate show
significant rank correlation with blood ammonia level. We
conclude that according to the results of MRS and the
observed correlations of white and grey matter Glx and
lactate concentrations with venous pH and ammonia levels,
ALF is expressed in alterations in the metabolism of both
grey and white matter brain tissue. Our MRS observations
were paralleled by elevated serum levels of ammonia,
bilirubin, aspartate aminotransferase and alanine amino-
transferase. Apart from the significant correlations between
CNS Glx with venous pH and of CNS lactate with blood
ammonia in the patients with ALF-related encephalopathy,
significant correlations of MRS parameters with any blood
liver function parameter were not observed in ALF or
control patients. The present results indicate that CNS Glx
and lactate primarily relate to hepatic detoxification
(ammonia, venous pH), rather than to liver parenchymal
integrity (aspartate aminotransferase, alanine aminotrans-
ferase) or biliary cholestasis (bilirubin, γ-glutamyl trans-
peptidase, alkaline phosphatase).
The added value of our results for treatment and
prognosis of children with ALF is limited. The brain
metabolites appear to correlate better with the abnormal
biochemistry than with clinical encephalopathy. One
inference that might be drawn is that these metabolite
changes are a direct reflection of the abnormal biochem-
istry, with the relationship to clinical encephalopathy
remaining just as elusive as without the MRS result. This
opens an opportunity for further discussion, which may be
addressed by an MRS study of subjects with ALF but
without encephalopathy.
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